{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:26:38Z","timestamp":1793042798748,"version":"4.5.0"},"reference-count":47,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Prophylactic Human Papillomavirus (HPV) vaccines prevent high-grade cervical lesions, but their role as adjuvant therapy after conization for high-grade cervical intraepithelial neoplasia (CIN2+) remains uncertain, particularly regarding vaccine type, timing, and margin status. This review aimed to quantify the effect of adjuvant HPV vaccination on CIN2+ recurrence after conization and to determine whether vaccine valency, timing of administration (before vs after surgery), and cone margin status modify this effect.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a PROSPERO-registered (CRD420251042109) systematic review and meta-analysis of randomized trials and cohort studies comparing HPV vaccination versus no vaccination in women treated with conization and\/or loop electrosurgical excision procedure (LEEP) for histologically confirmed CIN2+. The primary outcome was recurrent CIN2+; secondary outcomes were HPV persistence\/reinfection and vaccine-related adverse events. Random-effects models were used to pool risk ratios (RRs), with preplanned subgroup analyses by vaccine valency (bivalent, quadrivalent, nonavalent), timing of vaccination (before vs after conization), and cone margin status (positive vs negative), alongside sensitivity and GRADE certainty assessments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Seventeen studies (four randomized controlled trials [RCTs], thirteen cohorts), including 33,181 women (6,665 vaccinated; 26,516 unvaccinated), met inclusion criteria. Overall, adjuvant HPV vaccination was associated with a 62% relative reduction in CIN2+ recurrence (pooled RR 0.38, 95% confidence interval [CI] 0.29-0.51; I\u00b2 = 58.6%). Subgroup analyses showed similar benefit across valencies (bivalent RR 0.50, quadrivalent RR 0.37, nonavalent RR 0.41; p for subgroup difference = 0.94), vaccination before versus after conization (RR 0.57 vs 0.72; p = 0.35), and in both margin-negative (RR 0.34) and margin-positive (RR 0.40) women (p = 0.63). Data on HPV persistence suggested a predominantly prophylactic mechanism (prevention of new\/re-infection rather than clearance), and no new safety signals emerged.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Adjuvant prophylactic HPV vaccination meaningfully lowers CIN2+ recurrence after conization across vaccine types and clinical subgroups, supporting its integration into routine post-excisional care for eligible women as a low-burden strategy to reduce repeat procedures, preserve reproductive potential, and help avert progression to cervical cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic Review Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD420251042109<\/jats:ext-link>\n                      , identifier CRD420251042109.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1748972","type":"journal-article","created":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T05:32:35Z","timestamp":1771997555000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Impact of HPV vaccine on CIN2+ recurrence after conization: a systematic review and meta-analysis of vaccination timing, valency and surgical margins"],"prefix":"10.3389","volume":"16","author":[{"given":"Mauro Francesco Pio","family":"Maiorano","sequence":"first","affiliation":[{"name":"Unit of Obstetrics and Gynecology, Department of Interdisciplinary Medicine (DIM), University of Bari \u201cAldo Moro\u201d, Polyclinic of Bari","place":["Bari, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ambrogio","family":"Cazzolla","sequence":"additional","affiliation":[{"name":"Unit of Oncologic Gynecology, IRCCS \u201cGiovanni Paolo II\u201d Oncologic Institute","place":["Bari, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigida Anna","family":"Maiorano","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, IRCCS San Raffaele Hospital","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"Loizzi","sequence":"additional","affiliation":[{"name":"Unit of Oncologic Gynecology, IRCCS \u201cGiovanni Paolo II\u201d Oncologic Institute","place":["Bari, Italy"]},{"name":"Translational Biomedicine and Neuroscience Department (DiBraiN), University of Bari \u201cAldo Moro\u201d","place":["Bari, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gennaro","family":"Cormio","sequence":"additional","affiliation":[{"name":"Unit of Obstetrics and Gynecology, Department of Interdisciplinary Medicine (DIM), University of Bari \u201cAldo Moro\u201d, Polyclinic of Bari","place":["Bari, Italy"]},{"name":"Unit of Oncologic Gynecology, IRCCS \u201cGiovanni Paolo II\u201d Oncologic Institute","place":["Bari, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Colonna","sequence":"additional","affiliation":[{"name":"Unit of Oncologic Gynecology, IRCCS \u201cGiovanni Paolo II\u201d Oncologic Institute","place":["Bari, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Lopez","sequence":"additional","affiliation":[{"name":"Unit of Oncologic Gynecology, IRCCS \u201cGiovanni Paolo II\u201d Oncologic Institute","place":["Bari, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1080\/01443615.2019.1634030","article-title":"Human papillomavirus and cervical cancer","volume":"40","author":"Okunade","year":"2020","journal-title":"J Obstet Gynaecol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines12111293","article-title":"Human Papillomavirus (HPV) vaccination: Progress, challenges, and future directions in global immunization strategies","volume":"12","author":"Branda","year":"2024","journal-title":"Vaccines"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e077341","DOI":"10.1136\/bmj-2023-077341","article-title":"Effect of the HPV vaccination programme on incidence of cervical cancer and grade 3 cervical intraepithelial neoplasia by socioeconomic deprivation in England: Population-based observational study","volume":"385","author":"Falcaro","year":"2024","journal-title":"BMJ"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30068-4","article-title":"Impact of HPV vaccination and cervical screening on cervical cancer elimination: A comparative modelling analysis in 78 low-income and lower-middle-income countries","volume":"395","author":"Brisson","year":"2020","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1917338","article-title":"HPV vaccination and the risk of invasive cervical cancer","volume":"383","author":"Lei","year":"2020","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1080\/00016340802596009","article-title":"The efficacy of conservative management after conization in patients with stage IA1 microinvasive cervical carcinoma","volume":"88","author":"Lee","year":"2009","journal-title":"Acta Obstet Gynecol Scand"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2024.155283","article-title":"Reevaluation of negative cervical conizations: Frequency, diagnostic errors, risk factors and management","volume":"257","author":"Lorenset","year":"2024","journal-title":"Pathol Res Pract"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.7150\/jca.13503","article-title":"HPV-testing in follow-up of patients treated for CIN2+ lesions","volume":"7","author":"Mariani","year":"2016","journal-title":"J Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12247592","article-title":"Effect of HPV vaccination on virus disappearance in cervical samples of a cohort of HPV-positive Polish patients","volume":"12","author":"Pruski","year":"2023","journal-title":"J Clin Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9050410","article-title":"Adjuvant HPV vaccination to prevent recurrent cervical dysplasia after surgical treatment: A meta-analysis","volume":"9","author":"Di Donato","year":"2021","journal-title":"Vaccines"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e070135","DOI":"10.1136\/bmj-2022-070135","article-title":"Role of human papillomavirus (HPV) vaccination on HPV infection and recurrence of HPV-related disease after local surgical treatment: Systematic review and meta-analysis","volume":"378","author":"Kechagias","year":"2022","journal-title":"BMJ"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2025.101337","article-title":"Early and long-term effects of prophylactic and post-excision human papillomavirus vaccination on recurrent high-grade cervical intraepithelial neoplasia relative to margin status: A retrospective cohort study in the Czech Republic","volume":"55","author":"Petr\u00e1\u0161","year":"2025","journal-title":"Lancet Reg Health Eur"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2021.0522","article-title":"MOOSE reporting guidelines for meta-analyses of observational studies","volume":"156","author":"Brooke","year":"2021","journal-title":"JAMA Surg"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: A revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"B16","volume-title":"The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses","author":"Wells","year":"2014"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2006.04.004","article-title":"Random-effects model for meta-analysis of clinical trials: An update","volume":"28","author":"DerSimonian","year":"2007","journal-title":"Contemp Clin Trials"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.2307\/2332378","article-title":"The comparison of percentages in matched samples","volume":"37","author":"Cochran","year":"1950","journal-title":"Biometrika"},{"key":"B20","unstructured":"R: A language and environment for statistical computing\n          \n          \n          Vienna\n          R Foundation for Statistical Computing\n          \n          2021"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2013.04.050","article-title":"Is vaccination with quadrivalent HPV vaccine after loopelectrosurgical excision procedure effective in preventing recurrence in patients with high-grade cervical intraepithelial neoplasia (CIN2-3)","volume":"130","author":"Kang","year":"2013","journal-title":"Gynecol Oncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.ajog.2016.02.021","article-title":"Impact of human papillomavirus (HPV) 16 and 18 vaccination on prevalent infections and rates of cervical lesions after excisional treatment","volume":"215","author":"Hildesheim","year":"2016","journal-title":"Am J Obstet Gynecol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2018.08.033","article-title":"SPERANZA project: HPV vaccination after treatment for CIN2","volume":"151","author":"Ghelardi","year":"2018","journal-title":"Gynecol Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s00404-018-4926-y","article-title":"Indication of prophylactic vaccines as a tool for secondary prevention in HPV-linked disease","volume":"298","author":"Pieralli","year":"2018","journal-title":"Arch Gynecol Obstet"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32752","article-title":"Risk of cervical intraepithelial neoplasia grade 2 or worse after conization in relation to HPV vaccination status","volume":"147","author":"Sand","year":"2020","journal-title":"Int J Cancer"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.12892\/ejgo4628.2019","article-title":"Impact of the human papillomavirus vaccination on patients who underwent conization for high-grade cervical intraepithelial neoplasia","volume":"40","author":"Ortega-Quinonero","year":"2019","journal-title":"Eur J Gynaecol Oncol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1186\/s12889-020-8371-z","article-title":"Can the prophylactic quadrivalent HPV vaccine be used as a therapeutic agent in women with CIN? A randomized trial","volume":"20","author":"Karimi-Zarchi","year":"2020","journal-title":"BMC Public Health"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines8020245","article-title":"HPV vaccination as adjuvant to conization in women with cervical intraepithelial neoplasia: A study under real-life conditions","volume":"8","author":"Del Pino","year":"2020","journal-title":"Vaccines"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines8040717","article-title":"Assessing the long-term role of vaccination against HPV after loop electrosurgical excision procedure (LEEP): A propensity-score matched comparison","volume":"8","author":"Bogani","year":"2020","journal-title":"Vaccines"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines8010045","article-title":"Efficacy of HPV vaccination in women receiving LEEP for cervical dysplasia: A single institution\u2019s experience","volume":"8","author":"Petrillo","year":"2020","journal-title":"Vaccines"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1097\/LGT.0000000000000625","article-title":"Efficacy of human papillomavirus vaccination 4 years after conization for high-grade cervical neoplasia","volume":"25","author":"G\u00f3mez de la Rosa","year":"2021","journal-title":"J Low Genit Tract Dis"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10020288","article-title":"Effectiveness of prophylactic human papillomavirus vaccine in the prevention of recurrence in women conized for HSIL\/CIN 2-3: The VENUS study","volume":"10","author":"Casajuana-P\u00e9rez","year":"2022","journal-title":"Vaccines"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10060887","article-title":"HPV vaccination in women with cervical intraepithelial neoplasia undergoing excisional treatment: Insights into unsolved questions","volume":"10","author":"Henere","year":"2022","journal-title":"Vaccines"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejogrb.2023.04.014","article-title":"The efficacy of human papillomavirus prophylactic vaccination after conization in preventing cervical intraepithelial neoplasia recurrence: A prospective observational study in China","volume":"286","author":"Chen","year":"2023","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2024.2343552","article-title":"Reduced risk of CIN2+ recurrence in women immunized with a 9-valent HPV vaccine post-excision: Retrospective cohort study","volume":"20","author":"Dvor\u00e1k","year":"2024","journal-title":"Hum Vaccin Immunother"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1136\/sextrans-2023-055793","article-title":"Timing of HPV vaccination as adjuvant treatment of CIN2+ recurrence in women undergoing surgical excision: A meta-analysis and meta-regression","volume":"99","author":"Petr\u00e1\u0161","year":"2023","journal-title":"Sex Transm Infect"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanogw.2025.100007","article-title":"Adjuvant prophylactic human papillomavirus vaccination for prevention of recurrent high-grade cervical intraepithelial neoplasia lesions in women undergoing lesion surgical treatment (VACCIN): A multicentre, phase 4 randomised placebo-controlled trial in the Netherlands","volume":"1","author":"van de Laar","year":"2025","journal-title":"Lancet Obstet Gynaecol Womens Health"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1111\/1471-0528.13839","article-title":"Risk of preterm birth following surgical treatment for cervical disease: Executive summary of a recent symposium","volume":"123","author":"Sasieni","year":"2016","journal-title":"BJOG"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)68181-6","article-title":"Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: Systematic review and meta-analysis","volume":"367","author":"Kyrgiou","year":"2006","journal-title":"Lancet"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.2011.02944.x","article-title":"The risk of preterm birth following treatment for precancerous changes in the cervix: A systematic review and meta-analysis","volume":"118","author":"Bruinsma","year":"2011","journal-title":"BJOG"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000000174","article-title":"Loop electrosurgical excision procedure and risk of preterm birth: A systematic review and meta-analysis","volume":"123","author":"Conner","year":"2014","journal-title":"Obstet Gynecol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1097\/LGT.0000000000000703","article-title":"Adjuvant human papillomavirus vaccine for patients undergoing treatment for cervical intraepithelial neoplasia. ASCCP Committee Opinion","volume":"27","author":"Sharpless","year":"2023","journal-title":"J Low Genit Tract Dis"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000004000","article-title":"Human papillomavirus vaccination. ACOG Committee Opinion No. 809","volume":"136","year":"2020","journal-title":"Obstet Gynecol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000005106","article-title":"Adjuvant human papillomavirus vaccination after excisional procedure for cervical intraepithelial neoplasia: A cost-effectiveness analysis","volume":"141","author":"Chaiken","year":"2023","journal-title":"Obstet Gynecol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.pvr.2017.06.002","article-title":"HPV vaccination of immunocompromised hosts","volume":"4","author":"Garland","year":"2017","journal-title":"Papillomavirus Res"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3390\/v15071440","article-title":"Recent developments in human papillomavirus (HPV) vaccinology","volume":"15","author":"Williamson","year":"2023","journal-title":"Viruses"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9121413","article-title":"Human papillomavirus vaccine efficacy and effectiveness against cancer","volume":"9","author":"Kamolratanakul","year":"2021","journal-title":"Vaccines"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1748972\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T05:32:41Z","timestamp":1771997561000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1748972\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,25]]},"references-count":47,"alternative-id":["10.3389\/fonc.2026.1748972"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1748972","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,25]]},"article-number":"1748972"}}